MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The DSUR provides an annual safety update for the study in accordance with FDA expectations for ongoing clinical investigations. At the time of this submission, the Phase 2 study⦠Continue reading MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
External link. We are not responsible for the content.
Read more βMore From MAPS
MAPS Announces Dates for Psychedelic Science 2027; Early Bird Registrations Now Open
Denver, Colorado; May 13, 2026 βThe Multidisciplinary Association for Psychedelic Studies (MAPS) announced that early...
MAPS Welcomes Liana Gillooly and Andrew βMoβ Septimus to Board of Directors
SAN JOSE, CA; May 7, 2026 β The Multidisciplinary Association for Psychedelic Studies (MAPS) today announced the addi...
MAPS & State of Colorado Partner to Deliver Free Harm Reduction Training for First Responders
DENVER, May 5, 2026 β The Multidisciplinary Association for Psychedelic Studies (MAPS) announced a partnership with t...
Latest News
What Happens When You Feel Like Jesus After Taking Psychedelics?
Experts explain why some psychedelic trips end in claims of divinity β and when it becomes a problem. [...] Read More...
Truffles, therapy, disciplinary law β An OPEN perspective on the grey area in which (licensed) therapists operate in the Netherlands with regard to psychedelics
Read this article in Dutch here. On May 8, 2026, the Amsterdam Healthcare Disciplinary Board ruled on a significant c...
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Repeated microdosing of LSD (8 to 20 ΞΌg) may help improve daily mood, specifically increasing feelings of connection,...
Itβs all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relations...
Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study
About 1 in 15 young adults in the United States reported microdosing hallucinogens in the past year.
Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Low doses of psilocybin may reduce the frequency of migraine attacks, but a two-dose "pulsed" schedule did not show a...